/ /

Michael J. Elman, MD
Ranibizumab proves instrumental for DME patients in RIDE, RISE trials
Ranibizumab provided improvements in visual acuity and DR that were stable over the long term when the drug was administered on an as-needed regimen to patients with diabetic macular edema in the RIDE and RISE trials.

Poll

View Results